Novo Nordisk Stock Analysis

News

Novo Nordisk stock downgraded

Novo Nordisk Stock Drops After Earnings. It Got Worse.

The drugmaker Novo Nordisk is slated to report its second-quarter financial results early Wednesday, after shares plunged late last month when the company previewed its earnings report and cut its full-year guidance.

The Motley Fool on MSN · 1d

Massive News for Novo Nordisk Stock Investors!

Management told investors to expect slower sales and profit growth in 2025.

MarketBeat on MSN · 1d

Novo Nordisk Stock Sinks—But Is a Bottom Finally In?

Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than 43% in 2025. Even in the volatile medical stocks sector, that kind of underperformance can’t be overlooked.

15h

Novo Nordisk, Super Micro, Shopify: Trending Tickers

Novo Nordisk (NVO) stock is under pressure after reporting its weakest sales growth since 2021. Super Micro Computer (SMCI) ...

Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

GlobalData on MSN16h

Novo Nordisk’s diabetes and weight loss drug sales growth decelerates

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

8don MSN

European stocks close up; Novo Nordisk logs its biggest daily drop on record

European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest ...

AOL2mon

Novo Nordisk Stock: Is It Still a Smart Buy? - AOL

Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results